B-hCLDN18.2 BxPC-3|BioMice百奥动物

Common name	B-hCLDN18.2 BxPC-3	Catalog number	321827
Aliases	/	Disease	Pancreatic adenocarcinoma
Organism	Human	Strain	Human
Tissue types	Pancreas	Tissue	Pancreas

模型验证

Description

The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly. Human CLDN18.2 is highly expressed on the surface of B-hCLDN18.2 BxPC-3 cells.

Application

B-hCLDN18.2 BxPC-3 cells have the capability to establish tumors in vivo and can be used for efficacy studies.

Targeting strategy

Gene targeting strategy for B-hCLDN18.2 BxPC-3 cells. The exogenous promoter and human CLDN18.2 coding sequence were inserted into the BxPC-3 cells genome randomly.

Protein expression analysis

CLDN18.2 expression analysis in B-hCLDN18.2 BxPC-3 cells by flow cytometry. Single cell suspensions from B-hCLDN18.2 BxPC-3 cultures were stained with species-specific anti-CLDN18.2 antibody. Human CLDN18.2 was detected on the surface of B-hCLDN18.2 BxPC-3 cells. The 1-A04 clone of B-hCLDN18.2 BxPC-3 cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hCLDN18.2 BxPC-3 cells. B-hCLDN18.2 BxPC-3 cells (1x10⁷) and wild-type BxPC-3 cells (1x10⁷) were subcutaneously implanted into B-NDG mice (female, 9-week-old, n=5). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B) Body weight (Mean± SEM). Volume was expressed in mm³ using the formula: V=0.5 X long diameter X short diameter². As shown in panel A, B-hCLDN18.2 BxPC-3 cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hCLDN18.2 BxPC-3 cells were subcutaneously transplanted into B-NDG mice (n=5), and on 77 days post inoculation, tumor cells were harvested and assessed for human CLDN18.2 expression by flow cytometry. As shown, human CLDN18.2 was highly expressed on the surface of tumor cells. Therefore, B-hCLDN18.2 BxPC-3 cells can be used for in vivo efficacy studies of novel CLDN18.2 therapeutics.